Synthesis of Gemcitabine-Loaded PLGA Microparticles with Green Solvents.

ACS Omega

Department of Chemical Engineering, University of Castilla-La Mancha, Facultad de C.C. Químicas, Avda. Camilo José Cela 12, 13071 Ciudad Real, Spain.

Published: August 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The use of polymeric microparticles is widely recognized as an effective strategy for enhancing the bioavailability and biodistribution of both lipophilic and hydrophilic medications. In this study, PLGA microparticles loaded with the anticancer drug gemcitabine were synthesized by using a double emulsion process known as water-in-oil-in-water solvent evaporation. Notably, this is the first time that ethyl lactate, an FDA-approved green solvent, has been used for the microparticle synthesis. For comparison, other solvents, such as ethyl acetate and dichloromethane, were also tested. The smallest particle size was achieved, regardless of the PLA:PGA ratio of the polymer, when using ethyl lactate under the following operational conditions: a high homogenizer speed (12,000 rpm) and an initial polymeric solution concentration of 1.5% w/v. Under these conditions, the encapsulation efficiency reached 45% for PLGA 50:50 and 35% for PLGA 75:25. Microparticle analysis revealed a homogeneous distribution (100-150 μm range) and a spherical shape. Furthermore, Fourier transform infrared (FTIR) spectroscopy confirmed the presence of gemcitabine in the microparticles.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12332675PMC
http://dx.doi.org/10.1021/acsomega.5c06385DOI Listing

Publication Analysis

Top Keywords

plga microparticles
8
ethyl lactate
8
synthesis gemcitabine-loaded
4
plga
4
gemcitabine-loaded plga
4
microparticles
4
microparticles green
4
green solvents
4
solvents polymeric
4
polymeric microparticles
4

Similar Publications

Tuberculosis (TB) continues to cause significant global mortality, highlighting the need for improved drug delivery systems. The objective of this paper focuses in describing the formulation, optimization and in vivo assessment of rifampicin encapsulated PLGA microparticles for site-specific inhalation therapy. Microparticles for inhalation were produced by spray drying, and the DoE methodology was applied to reach the most suitable aerodynamic properties (mass median aerodynamics diameter (MMAD) 2.

View Article and Find Full Text PDF

Cholesterol-Functionalized Porous PLA Microparticles for Enhanced Drug Delivery.

ACS Appl Bio Mater

September 2025

Innovation in Materials and Molecular Engineering - Biomaterials for Regenerative Therapies (IMEM-BRT) Group, Departament d'Enginyeria Química, EEBE, Universitat Politècnica de Catalunya, C/Eduard Maristany 10-14, Building I, second floor, Barcelona 08019, Spain.

A drug delivery platform based on highly porous poly(lactic acid) (PLA) microparticles functionalized with amphiphilic poly(ethylene glycol)-cholesterol (PEG-Chol) has been developed and successfully validated . This hybrid system addresses key limitations of conventional PLA and poly(lactide--glycolide) (PLGA) nanoparticles, providing better encapsulation and sustained drug release. The incorporation of PEG-Chol provides both enhanced aqueous dispersibility for prolonged circulation and membrane-anchoring capabilities, thereby promoting cellular interaction and endocytosis.

View Article and Find Full Text PDF

Purpose: Postsurgical pain (PSP) is a common complication in surgical patients that can progress to chronic pain and opioid dependence. Current analgesics, including opioids and non-opioid agents, are limited by short durations of action and adverse effects. This study reports the development and evaluation of extended-release bupivacaine microparticles (BuMPs) designed to provide sustained local analgesia and improve post-surgical pain management.

View Article and Find Full Text PDF

Postoperative ocular inflammation is a frequent complication of eye surgeries commonly managed using corticosteroids or nonsteroidal anti-inflammatory drug (NSAIDs) eye drops. However, poor ocular bioavailability and patient non-adherence due to frequent dosing limit the therapeutic efficacy of conventional eye drops. This study aimed to develop a sustained-release ocular insert containing bromfenac sodium (BS)-loaded poly(lactic-co-glycolic acid) (PLGA) microparticles (MPs) with an initial 3% (/) free BS fraction incorporated into a poly(vinyl alcohol) (PVA) matrix designed to achieve a dual-phase release profile for improved postoperative therapy.

View Article and Find Full Text PDF

Controlled release systems, such as polymeric microparticles (MPs), have emerged as a promising solution to extend the bioavailability and reduce dosing frequency for biologic drugs; however, the formulation of these systems to encapsulate highly sensitive, hydrophilic biologic drugs within hydrophobic polymers remains a nontrivial task. Although scalable manufacturing and FDA approval of single emulsion processes encapsulating small molecules has been achieved, scaling more complex double emulsion processes to encapsulate hydrophilic biologics remains more challenging. : Here, we demonstrate that two hydrophilic, low-molecular-weight, recombinant chemokines, CCL22 and CCL2, can be encapsulated in poly(lactic-co-glycolic acid) (PLGA) MPs using a single emulsion method where the proteins are dissolved in an organic solvent during formulation.

View Article and Find Full Text PDF